Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Construction in Progress (2016 - 2025)

Heron Therapeutics' Construction in Progress history spans 12 years, with the latest figure at $1.7 million for Q4 2025.

  • For Q4 2025, Construction in Progress fell 34.62% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $1.7 million, down 34.62%, while the annual FY2025 figure was $1.7 million, 34.62% down from the prior year.
  • Construction in Progress reached $1.7 million in Q4 2025 per HRTX's latest filing, down from $2.6 million in the prior quarter.
  • In the past five years, Construction in Progress ranged from a high of $15.9 million in Q4 2021 to a low of $1.7 million in Q4 2025.
  • Average Construction in Progress over 5 years is $6.4 million, with a median of $5.4 million recorded in 2022.
  • Peak YoY movement for Construction in Progress: tumbled 66.04% in 2022, then increased 16.67% in 2023.
  • A 5-year view of Construction in Progress shows it stood at $15.9 million in 2021, then crashed by 66.04% to $5.4 million in 2022, then increased by 16.67% to $6.3 million in 2023, then plummeted by 58.73% to $2.6 million in 2024, then plummeted by 34.62% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Construction in Progress are $1.7 million (Q4 2025), $2.6 million (Q4 2024), and $6.3 million (Q4 2023).